Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Open Access
- 1 January 2009
- journal article
- review article
- Published by Informa UK Limited in mAbs
- Vol. 1 (1), 41-48
- https://doi.org/10.4161/mabs.1.1.7509
Abstract
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This review focuses on the unique functional characteristics of nimotuzumab. Also, it discusses the safety and efficacy data obtained from the Phase IIb clinical trial conducted in India in SCCHN. Post Marketing Surveillance data from Cuba for the use of nimotuzumab in pediatric and adult glioma is also discussed. Overall, nimotuzumab has immense therapeutic potential in cancers of epithelial origin.Keywords
This publication has 17 references indexed in Scilit:
- Biological Activity In Vitro of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different AffinitiesHybridoma, 2007
- Incidence and management of cutaneous toxicities associated with cetuximabExpert Opinion on Drug Safety, 2007
- Dermatologic side effects associated with the epidermal growth factor receptor inhibitorsJournal of the American Academy of Dermatology, 2006
- Nimotuzumab: Evidence of Clinical Benefit Without RashThe Oncologist, 2005
- Recent developments related to the EGFR as a target for cancer chemotherapyCurrent Opinion in Pharmacology, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer PatientsJournal of Clinical Oncology, 2004
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibodyInternational Journal of Cancer, 2002
- A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sectionsJournal of Cellular Biochemistry, 1992